Cart
sales@molnova.com
BI-2852
CAS No. 2375482-51-0
BI-2852( —— )
Catalog No. M24089 CAS No. 2375482-51-0
BI-2852 is a KRAS inhibitor for the switch I/II pocket (SI/II-pocket) with nanomolar affinity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 262 | In Stock |
|
| 10MG | 389 | In Stock |
|
| 25MG | 644 | In Stock |
|
| 50MG | 888 | In Stock |
|
| 100MG | 1224 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBI-2852
-
NoteResearch use only, not for human use.
-
Brief DescriptionBI-2852 is a KRAS inhibitor for the switch I/II pocket (SI/II-pocket) with nanomolar affinity.
-
DescriptionBI-2852 is a KRAS inhibitor for the switch I/II pocket (SI/II-pocket) with nanomolar affinity. BI-2852 is leading to inhibition of downstream signaling and an antiproliferative effect in KRAS mutant cells.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
TargetRas
-
RecptorKRAS G12C
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2375482-51-0
-
Formula Weight516.59
-
Molecular FormulaC31H28N6O2
-
Purity>98% (HPLC)
-
SolubilityDMSO:55 mg/mL (106.47 mM; Need ultrasonic)
-
SMILESCn1cnc(Cn(cc2)c3c2ccc(CNCc2c([C@H](c4c5ccc(O)c4)NC5=O)c(cccc4)c4[nH]2)c3)c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Kessler D, et al. Drugging an undruggable pocket on KRAS. Proc Natl Acad Sci U S A. 2019 Aug 6; 116(32):15823-15829.
molnova catalog
related products
-
BAY-293 racemate
BAY-293 racemate (BAY293 racemate) is a potent SOS1 inhibitor that disrupts the KRAS-SOS1 interaction with IC50 of 50 nM。
-
ARS-1323-alkyne
ARS-1323-alkyne is a switch-II pocket (S-IIP) inhibitor and a conformational specific chemical reporter of KRASG12C nucleotide state in living cells.
-
Sotorasib
Sotorasib (AMG-510) racemate is the racemate of Sotorasib (AMG-510). AMG-510 is a potent, orally bioavailable, and selective KRAS G12C covalent inhibitor with anti-tumor activity.
